262 related articles for article (PubMed ID: 9696850)
1. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.
Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A
J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
[TBL] [Abstract][Full Text] [Related]
3. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
[TBL] [Abstract][Full Text] [Related]
4. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
[TBL] [Abstract][Full Text] [Related]
5. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
7. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
[TBL] [Abstract][Full Text] [Related]
8. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
9. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
10. Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness.
Brann TW; Dewar RL; Jiang MK; Shah A; Nagashima K; Metcalf JA; Falloon J; Lane HC; Imamichi T
J Virol; 2006 Jun; 80(12):6136-45. PubMed ID: 16731952
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
12. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Dekhtyar T; Ng TI; Lu L; Masse S; DeGoey DA; Flosi WJ; Grampovnik DJ; Klein LL; Kempf DJ; Molla A
Antimicrob Agents Chemother; 2008 Apr; 52(4):1337-44. PubMed ID: 18212102
[TBL] [Abstract][Full Text] [Related]
14. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
Pazhanisamy S; Stuver CM; Cullinan AB; Margolin N; Rao BG; Livingston DJ
J Biol Chem; 1996 Jul; 271(30):17979-85. PubMed ID: 8663409
[TBL] [Abstract][Full Text] [Related]
15. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
16. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA
J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
[TBL] [Abstract][Full Text] [Related]
17. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
[TBL] [Abstract][Full Text] [Related]
18. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
19. In vitro selection and characterization of VX-478 resistant HIV-1 variants.
Pazhanisamy S; Partaledis JA; Rao BG; Livingston DJ
Adv Exp Med Biol; 1998; 436():75-83. PubMed ID: 9561202
[TBL] [Abstract][Full Text] [Related]
20. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
Doyon L; Croteau G; Thibeault D; Poulin F; Pilote L; Lamarre D
J Virol; 1996 Jun; 70(6):3763-9. PubMed ID: 8648711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
